No Data
Peering Into Natera's Recent Short Interest
Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
Eli Lilly Bets $409M for AI-focused Drug Discovery
Perspective Gets FDA Fast Track Status for Radiopharmaceutical VMT101
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Eli Lilly Shares Are Trading Lower. The Company Announced Topline Results From the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa in Adults With Type 2 Diabetes Using Basal Insulin for the First Time and in...